Results 101 to 110 of about 3,779 (178)

Long-term effects of denosumab: a 10-year single-center retrospective study. [PDF]

Arch Osteoporos
Aldegheri F, Appoloni M, Passoni N, Zibordi V, Rossini M, Gatti D, Adami G, Pollastri F, Fassio A, Viapiana O.   +9 more
europepmc   +1 more source

Diphosphonates and Bone

Japanese journal of bone and mineral metabolism, 1983
openaire   +1 more source

Non-union after bisphosphonate-associated atypical femoral fractures: a review of the current literature. [PDF]

Eur J Orthop Surg Traumatol
Dowling J, Marsh S, O'Grady J.
europepmc   +1 more source

Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers. [PDF]

Br J Haematol
Gundesen MT, Vangsted AJ, Helleberg C, Haukås E, Silkjær T, Madsen JS, Asmussen JT, Teodorescu EM, Jensen BA, Slørdahl TS, Nielsen AA, Olsen DA, Søe K, Nahi H, Waage A, Abildgaard N, Schjesvold F, Lund T.   +17 more
europepmc   +1 more source

Mortality following atypical femoral fractures in men. [PDF]

J Bone Miner Res
Hoffer C, Obremskey W, Makkar B, Basida B, Shah N, Huling JD, Huo Z, Budde E, Jacob R, Schousboe JT, Fink HA, Adler RA, Lo JC, Avidano R, Barzilay JI, Weaver F, Ott SM, Lien K, Carbone LD.   +18 more
europepmc   +1 more source

Bisphosphonate and statin: adverse effects of co-medication on wound healing in in vitro models of periodontal tissues. [PDF]

Acta Odontol Scand
Småland-Reksten A, Agger AE, Lian AM, Reseland JE, Krüger TB.   +4 more
europepmc   +1 more source

Letter: Bisphosphonate effectiveness in patients with cirrhosis-an emulated clinical trial. Authors' reply. [PDF]

Aliment Pharmacol Ther
Tapper EB, Parikh ND.
europepmc   +1 more source

Cardiac phenotype in hereditary transthyretin amyloidosis: correlations between fibril types and 99mTc-DPD uptake. [PDF]

Sci Rep
Löfbacka V, Wixner J, Westermark P, Vesterlund JD, Anan I, Pilebro B.   +5 more
europepmc   +1 more source

Postmenopausal Osteoporosis, Endothelial Dysfunction, and Cardiovascular Risk. [PDF]

J Clin Rheumatol
Pickering ME, Heiss C, Morel V, Pickering G, Couderc M, Mathieu S, Malochet-Guinamand S, Durif J, Sapin V, Pereira B, Tournadre A, Chapurlat R.   +11 more
europepmc   +1 more source

Site-specific predictors of bone mineral density response to zoledronic acid in postmenopausal osteoporosis: differential roles of bone turnover markers and body mass index across skeletal sites. [PDF]

BMC Womens Health
Xu C, Xu Y, Bian P.
europepmc   +1 more source